Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
322 studies found for:    Open Studies | "Carcinoma, Renal Cell"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
Conditions: Locally Advanced and/or Metastatic Renal Cell Carcinoma;   Carcinoma, Renal Cell;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Pazopanib
2 Unknown  Treatment of Patients With Advanced Renal Cancer With a Radio-labeled Antibody, Yttrium-90 Conjugated Chimeric G250
Conditions: Renal Cell Carcinoma;   Kidney Neoplasm;   Renal Cancer;   Kidney Cancer
Intervention: Drug: Yttrium-90 conjugated chimeric G250 (90Y-cG250)
3 Recruiting A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma;   Clear-cell Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Kidney Diseases;   Kidney Neoplasms;   Metastatic Renal Cell Carcinoma
Intervention: Drug: CDX-014
4 Recruiting Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors
Conditions: Carcinoma, Renal Cell;   Clear Cell Renal Cell Carcinoma
Intervention: Drug: axitinib
5 Recruiting A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Conditions: Carcinoma, Renal Cell;   Kidney Diseases;   Kidney Neoplasms;   Urogenital Neoplasms;   Urologic Diseases;   Urologic Neoplasms;   Neoplasms;   Neoplasms by Histologic Type;   Clear-cell Metastatic Renal Cell Carcinoma
Intervention: Drug: Combination of varlilumab and sunitinib
6 Not yet recruiting Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial
Conditions: Renal Cell Carcinoma;   Kidney Cancer
Interventions: Drug: Sunitinib;   Drug: Isoquercetin;   Drug: Placebo
7 Recruiting Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
Condition: Carcinoma, Renal Cell
Interventions: Drug: Sunitinib;   Drug: Temsirolimus;   Drug: Sorafenib;   Drug: Pazopanib;   Drug: Everolimus;   Drug: Axitinib
8 Unknown  Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)
Condition: Carcinoma, Renal Cell
Interventions: Drug: Pazopanib;   Device: DCE-MRI and Quantitative Doppler Ultrasound
9 Recruiting Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma
Condition: Carcinoma, Renal Cell
Intervention: Drug: Pazopanib followed by everolimus
10 Recruiting Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC)
Condition: Carcinoma, Renal Cell
Interventions: Drug: Pazopanib;   Drug: MK-3475
11 Recruiting Prognostic Significance of Preoperative Hemoglobin A1c (HbA1c) in Renal Cell Carcinoma
Conditions: Carcinoma, Renal Cell;   Pathology;   Treatment Outcome;   Hemoglobin A1c Protein, Human
Intervention:
12 Recruiting Myeloid Derived Suppressor Cells Clinical Assay in Finding and Monitoring Kidney Cancer
Conditions: Healthy Subject;   Metastatic Renal Cell Cancer;   Recurrent Renal Cell Carcinoma;   Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer;   Stage III Renal Cell Cancer
Interventions: Procedure: Computed Tomography;   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis;   Procedure: Magnetic Resonance Imaging
13 Recruiting Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Conditions: Carcinoma of the Collecting Ducts of Bellini;   Chromophobe Renal Cell Carcinoma;   Kidney Medullary Carcinoma;   Kidney Oncocytoma;   Papillary Renal Cell Carcinoma;   Recurrent Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
Intervention: Drug: Pazopanib Hydrochloride
14 Recruiting Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Conditions: Recurrent Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Drug: Crizotinib;   Other: Laboratory Biomarker Analysis;   Drug: Sunitinib Malate;   Drug: Volitinib
15 Recruiting Nivolumab in Treating Patients With HIgh-Risk Non-Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer;   Stage III Renal Cell Cancer
Interventions: Procedure: Conventional Surgery;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
16 Recruiting Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Metastatic Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Biological: Aldesleukin;   Procedure: Computed Tomography;   Drug: Entinostat;   Radiation: Fludeoxyglucose F-18;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Procedure: Positron Emission Tomography
17 Recruiting A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma
Conditions: ccRCC;   RCC;   Kidney Cancer;   Clear Cell Renal Cell Carcinoma;   Renal Cell Carcinoma
Interventions: Drug: PART 1: PT2385 Tablets;   Drug: PART 2: PT2385 Tablets in combination with nivolumab
18 Recruiting Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer
Conditions: Recurrent Renal Cell Carcinoma;   Stage I Renal Cell Cancer;   Stage II Renal Cell Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Procedure: Nephrectomy;   Biological: Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003
19 Recruiting Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
Conditions: Metastatic Renal Cell Cancer;   Recurrent Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Radiation: Stereotactic Body Radiation Therapy
20 Recruiting Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma;   Hereditary Leiomyomatosis and Renal Cell Cancer;   Papillary Renal Cell Carcinoma, Sporadic
Interventions: Drug: Vandetanib;   Drug: Metformin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years